Alarm as FDA fast-tracks first antipsychotic drug for agitation in dementia
In trials, the antipsychotic drug brexpiprazole (Rexulti) failed to provide a clinically meaningful benefit and increased the risk of death. Yet the US Food and Drug Administration (FDA) has fast tracked its approval, making ...
Aug 17, 2023
3
117